nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—Oxymorphone—CYP3A4—bone cancer	0.00697	0.183	CrCbGaD
Naltrexone—Hydrocodone—CYP3A4—bone cancer	0.00609	0.16	CrCbGaD
Naltrexone—Oxycodone—CYP3A4—bone cancer	0.00556	0.146	CrCbGaD
Naltrexone—Buprenorphine—CYP3A4—bone cancer	0.00512	0.134	CrCbGaD
Naltrexone—Naloxone—CYP3A4—bone cancer	0.00509	0.133	CrCbGaD
Naltrexone—Hydromorphone—CYP3A4—bone cancer	0.00505	0.132	CrCbGaD
Naltrexone—Morphine—CYP3A4—bone cancer	0.00429	0.112	CrCbGaD
Naltrexone—Paraesthesia—Cisplatin—bone cancer	0.00216	0.00225	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Methotrexate—bone cancer	0.00215	0.00225	CcSEcCtD
Naltrexone—Dyspnoea—Cisplatin—bone cancer	0.00214	0.00223	CcSEcCtD
Naltrexone—Abdominal pain upper—Doxorubicin—bone cancer	0.00212	0.00221	CcSEcCtD
Naltrexone—Angina pectoris—Epirubicin—bone cancer	0.00211	0.0022	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.00209	0.00218	CcSEcCtD
Naltrexone—Decreased appetite—Cisplatin—bone cancer	0.00209	0.00218	CcSEcCtD
Naltrexone—Bronchitis—Epirubicin—bone cancer	0.00209	0.00218	CcSEcCtD
Naltrexone—Pneumonia—Methotrexate—bone cancer	0.00208	0.00217	CcSEcCtD
Naltrexone—Nasopharyngitis—Doxorubicin—bone cancer	0.00208	0.00217	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Cisplatin—bone cancer	0.00207	0.00216	CcSEcCtD
Naltrexone—Infestation NOS—Methotrexate—bone cancer	0.00207	0.00216	CcSEcCtD
Naltrexone—Infestation—Methotrexate—bone cancer	0.00207	0.00216	CcSEcCtD
Naltrexone—Depression—Methotrexate—bone cancer	0.00206	0.00215	CcSEcCtD
Naltrexone—Pain—Cisplatin—bone cancer	0.00205	0.00214	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.00205	0.00214	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Epirubicin—bone cancer	0.00202	0.0021	CcSEcCtD
Naltrexone—Conjunctivitis—Methotrexate—bone cancer	0.00201	0.00209	CcSEcCtD
Naltrexone—Influenza—Doxorubicin—bone cancer	0.00201	0.00209	CcSEcCtD
Naltrexone—Feeling abnormal—Cisplatin—bone cancer	0.00198	0.00206	CcSEcCtD
Naltrexone—Weight increased—Epirubicin—bone cancer	0.00197	0.00206	CcSEcCtD
Naltrexone—Weight decreased—Epirubicin—bone cancer	0.00196	0.00205	CcSEcCtD
Naltrexone—Angina pectoris—Doxorubicin—bone cancer	0.00196	0.00204	CcSEcCtD
Naltrexone—Hepatobiliary disease—Methotrexate—bone cancer	0.00195	0.00204	CcSEcCtD
Naltrexone—Epistaxis—Methotrexate—bone cancer	0.00195	0.00203	CcSEcCtD
Naltrexone—Pneumonia—Epirubicin—bone cancer	0.00195	0.00203	CcSEcCtD
Naltrexone—Infestation—Epirubicin—bone cancer	0.00193	0.00202	CcSEcCtD
Naltrexone—Infestation NOS—Epirubicin—bone cancer	0.00193	0.00202	CcSEcCtD
Naltrexone—Bronchitis—Doxorubicin—bone cancer	0.00193	0.00201	CcSEcCtD
Naltrexone—Body temperature increased—Cisplatin—bone cancer	0.0019	0.00198	CcSEcCtD
Naltrexone—Conjunctivitis—Epirubicin—bone cancer	0.00188	0.00196	CcSEcCtD
Naltrexone—Urinary tract infection—Epirubicin—bone cancer	0.00188	0.00196	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00187	0.00195	CcSEcCtD
Naltrexone—Hepatitis—Methotrexate—bone cancer	0.00186	0.00193	CcSEcCtD
Naltrexone—Pharyngitis—Methotrexate—bone cancer	0.00184	0.00192	CcSEcCtD
Naltrexone—Hepatobiliary disease—Epirubicin—bone cancer	0.00183	0.00191	CcSEcCtD
Naltrexone—Weight increased—Doxorubicin—bone cancer	0.00183	0.0019	CcSEcCtD
Naltrexone—Epistaxis—Epirubicin—bone cancer	0.00182	0.0019	CcSEcCtD
Naltrexone—Weight decreased—Doxorubicin—bone cancer	0.00182	0.00189	CcSEcCtD
Naltrexone—Sinusitis—Epirubicin—bone cancer	0.00181	0.00189	CcSEcCtD
Naltrexone—Pneumonia—Doxorubicin—bone cancer	0.0018	0.00188	CcSEcCtD
Naltrexone—Infestation NOS—Doxorubicin—bone cancer	0.00179	0.00187	CcSEcCtD
Naltrexone—Infestation—Doxorubicin—bone cancer	0.00179	0.00187	CcSEcCtD
Naltrexone—Hypersensitivity—Cisplatin—bone cancer	0.00177	0.00185	CcSEcCtD
Naltrexone—Conjunctivitis—Doxorubicin—bone cancer	0.00174	0.00181	CcSEcCtD
Naltrexone—Urinary tract infection—Doxorubicin—bone cancer	0.00174	0.00181	CcSEcCtD
Naltrexone—Hepatitis—Epirubicin—bone cancer	0.00174	0.00181	CcSEcCtD
Naltrexone—Eye disorder—Methotrexate—bone cancer	0.00173	0.00181	CcSEcCtD
Naltrexone—Tinnitus—Methotrexate—bone cancer	0.00173	0.0018	CcSEcCtD
Naltrexone—Asthenia—Cisplatin—bone cancer	0.00172	0.0018	CcSEcCtD
Naltrexone—Pharyngitis—Epirubicin—bone cancer	0.00172	0.0018	CcSEcCtD
Naltrexone—Cardiac disorder—Methotrexate—bone cancer	0.00172	0.0018	CcSEcCtD
Naltrexone—Connective tissue disorder—Epirubicin—bone cancer	0.00171	0.00178	CcSEcCtD
Naltrexone—Hepatobiliary disease—Doxorubicin—bone cancer	0.00169	0.00176	CcSEcCtD
Naltrexone—Epistaxis—Doxorubicin—bone cancer	0.00169	0.00176	CcSEcCtD
Naltrexone—Angiopathy—Methotrexate—bone cancer	0.00168	0.00176	CcSEcCtD
Naltrexone—Sinusitis—Doxorubicin—bone cancer	0.00168	0.00175	CcSEcCtD
Naltrexone—Immune system disorder—Methotrexate—bone cancer	0.00168	0.00175	CcSEcCtD
Naltrexone—Mediastinal disorder—Methotrexate—bone cancer	0.00167	0.00174	CcSEcCtD
Naltrexone—Chills—Methotrexate—bone cancer	0.00166	0.00174	CcSEcCtD
Naltrexone—Diarrhoea—Cisplatin—bone cancer	0.00164	0.00171	CcSEcCtD
Naltrexone—Alopecia—Methotrexate—bone cancer	0.00164	0.00171	CcSEcCtD
Naltrexone—Mental disorder—Methotrexate—bone cancer	0.00163	0.00169	CcSEcCtD
Naltrexone—Eye disorder—Epirubicin—bone cancer	0.00162	0.00169	CcSEcCtD
Naltrexone—Tinnitus—Epirubicin—bone cancer	0.00162	0.00169	CcSEcCtD
Naltrexone—Malnutrition—Methotrexate—bone cancer	0.00161	0.00168	CcSEcCtD
Naltrexone—Cardiac disorder—Epirubicin—bone cancer	0.00161	0.00168	CcSEcCtD
Naltrexone—Hepatitis—Doxorubicin—bone cancer	0.00161	0.00168	CcSEcCtD
Naltrexone—Pharyngitis—Doxorubicin—bone cancer	0.00159	0.00166	CcSEcCtD
Naltrexone—Dysgeusia—Methotrexate—bone cancer	0.00158	0.00165	CcSEcCtD
Naltrexone—Connective tissue disorder—Doxorubicin—bone cancer	0.00158	0.00165	CcSEcCtD
Naltrexone—Angiopathy—Epirubicin—bone cancer	0.00158	0.00164	CcSEcCtD
Naltrexone—Immune system disorder—Epirubicin—bone cancer	0.00157	0.00164	CcSEcCtD
Naltrexone—Mediastinal disorder—Epirubicin—bone cancer	0.00156	0.00163	CcSEcCtD
Naltrexone—Back pain—Methotrexate—bone cancer	0.00156	0.00163	CcSEcCtD
Naltrexone—Chills—Epirubicin—bone cancer	0.00156	0.00162	CcSEcCtD
Naltrexone—Alopecia—Epirubicin—bone cancer	0.00153	0.0016	CcSEcCtD
Naltrexone—Vomiting—Cisplatin—bone cancer	0.00153	0.00159	CcSEcCtD
Naltrexone—Vision blurred—Methotrexate—bone cancer	0.00152	0.00159	CcSEcCtD
Naltrexone—Mental disorder—Epirubicin—bone cancer	0.00152	0.00159	CcSEcCtD
Naltrexone—Rash—Cisplatin—bone cancer	0.00151	0.00158	CcSEcCtD
Naltrexone—Dermatitis—Cisplatin—bone cancer	0.00151	0.00158	CcSEcCtD
Naltrexone—Malnutrition—Epirubicin—bone cancer	0.00151	0.00158	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—bone cancer	0.0015	0.00157	CcSEcCtD
Naltrexone—Ill-defined disorder—Methotrexate—bone cancer	0.0015	0.00156	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—bone cancer	0.0015	0.00156	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—bone cancer	0.00149	0.00155	CcSEcCtD
Naltrexone—Flatulence—Epirubicin—bone cancer	0.00149	0.00155	CcSEcCtD
Naltrexone—Tension—Epirubicin—bone cancer	0.00148	0.00155	CcSEcCtD
Naltrexone—Dysgeusia—Epirubicin—bone cancer	0.00148	0.00154	CcSEcCtD
Naltrexone—Nervousness—Epirubicin—bone cancer	0.00147	0.00153	CcSEcCtD
Naltrexone—Back pain—Epirubicin—bone cancer	0.00146	0.00152	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—bone cancer	0.00146	0.00152	CcSEcCtD
Naltrexone—Malaise—Methotrexate—bone cancer	0.00146	0.00152	CcSEcCtD
Naltrexone—Muscle spasms—Epirubicin—bone cancer	0.00145	0.00152	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—bone cancer	0.00145	0.00151	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—bone cancer	0.00145	0.00151	CcSEcCtD
Naltrexone—Chills—Doxorubicin—bone cancer	0.00144	0.0015	CcSEcCtD
Naltrexone—Nausea—Cisplatin—bone cancer	0.00143	0.00149	CcSEcCtD
Naltrexone—Vision blurred—Epirubicin—bone cancer	0.00142	0.00149	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—bone cancer	0.00142	0.00148	CcSEcCtD
Naltrexone—Cough—Methotrexate—bone cancer	0.00141	0.00147	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—bone cancer	0.00141	0.00147	CcSEcCtD
Naltrexone—Ill-defined disorder—Epirubicin—bone cancer	0.0014	0.00146	CcSEcCtD
Naltrexone—Convulsion—Methotrexate—bone cancer	0.0014	0.00146	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—bone cancer	0.0014	0.00146	CcSEcCtD
Naltrexone—Agitation—Epirubicin—bone cancer	0.00139	0.00145	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—bone cancer	0.00138	0.00144	CcSEcCtD
Naltrexone—Chest pain—Methotrexate—bone cancer	0.00137	0.00143	CcSEcCtD
Naltrexone—Arthralgia—Methotrexate—bone cancer	0.00137	0.00143	CcSEcCtD
Naltrexone—Myalgia—Methotrexate—bone cancer	0.00137	0.00143	CcSEcCtD
Naltrexone—Tension—Doxorubicin—bone cancer	0.00137	0.00143	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—bone cancer	0.00137	0.00143	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00137	0.00142	CcSEcCtD
Naltrexone—Malaise—Epirubicin—bone cancer	0.00136	0.00142	CcSEcCtD
Naltrexone—Discomfort—Methotrexate—bone cancer	0.00136	0.00142	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—bone cancer	0.00136	0.00142	CcSEcCtD
Naltrexone—Syncope—Epirubicin—bone cancer	0.00136	0.00141	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—bone cancer	0.00135	0.00141	CcSEcCtD
Naltrexone—Muscle spasms—Doxorubicin—bone cancer	0.00134	0.0014	CcSEcCtD
Naltrexone—Palpitations—Epirubicin—bone cancer	0.00134	0.00139	CcSEcCtD
Naltrexone—Confusional state—Methotrexate—bone cancer	0.00133	0.00139	CcSEcCtD
Naltrexone—Loss of consciousness—Epirubicin—bone cancer	0.00133	0.00139	CcSEcCtD
Naltrexone—Cough—Epirubicin—bone cancer	0.00132	0.00138	CcSEcCtD
Naltrexone—Anaphylactic shock—Methotrexate—bone cancer	0.00132	0.00137	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—bone cancer	0.00132	0.00137	CcSEcCtD
Naltrexone—Convulsion—Epirubicin—bone cancer	0.00131	0.00137	CcSEcCtD
Naltrexone—Infection—Methotrexate—bone cancer	0.00131	0.00137	CcSEcCtD
Naltrexone—Hypertension—Epirubicin—bone cancer	0.0013	0.00136	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—bone cancer	0.0013	0.00135	CcSEcCtD
Naltrexone—Nervous system disorder—Methotrexate—bone cancer	0.00129	0.00135	CcSEcCtD
Naltrexone—Arthralgia—Epirubicin—bone cancer	0.00129	0.00134	CcSEcCtD
Naltrexone—Myalgia—Epirubicin—bone cancer	0.00129	0.00134	CcSEcCtD
Naltrexone—Chest pain—Epirubicin—bone cancer	0.00129	0.00134	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—bone cancer	0.00129	0.00134	CcSEcCtD
Naltrexone—Anxiety—Epirubicin—bone cancer	0.00128	0.00134	CcSEcCtD
Naltrexone—Skin disorder—Methotrexate—bone cancer	0.00128	0.00134	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00128	0.00133	CcSEcCtD
Naltrexone—Hyperhidrosis—Methotrexate—bone cancer	0.00127	0.00133	CcSEcCtD
Naltrexone—Discomfort—Epirubicin—bone cancer	0.00127	0.00133	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—bone cancer	0.00126	0.00132	CcSEcCtD
Naltrexone—Dry mouth—Epirubicin—bone cancer	0.00126	0.00131	CcSEcCtD
Naltrexone—Anorexia—Methotrexate—bone cancer	0.00126	0.00131	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—bone cancer	0.00125	0.00131	CcSEcCtD
Naltrexone—Confusional state—Epirubicin—bone cancer	0.00124	0.0013	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—bone cancer	0.00124	0.00129	CcSEcCtD
Naltrexone—Anaphylactic shock—Epirubicin—bone cancer	0.00123	0.00129	CcSEcCtD
Naltrexone—Oedema—Epirubicin—bone cancer	0.00123	0.00129	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—bone cancer	0.00123	0.00128	CcSEcCtD
Naltrexone—Infection—Epirubicin—bone cancer	0.00123	0.00128	CcSEcCtD
Naltrexone—Cough—Doxorubicin—bone cancer	0.00122	0.00127	CcSEcCtD
Naltrexone—Shock—Epirubicin—bone cancer	0.00121	0.00127	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—bone cancer	0.00121	0.00126	CcSEcCtD
Naltrexone—Nervous system disorder—Epirubicin—bone cancer	0.00121	0.00126	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—bone cancer	0.00121	0.00126	CcSEcCtD
Naltrexone—Tachycardia—Epirubicin—bone cancer	0.0012	0.00126	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Methotrexate—bone cancer	0.0012	0.00125	CcSEcCtD
Naltrexone—Skin disorder—Epirubicin—bone cancer	0.0012	0.00125	CcSEcCtD
Naltrexone—Hyperhidrosis—Epirubicin—bone cancer	0.00119	0.00124	CcSEcCtD
Naltrexone—Insomnia—Methotrexate—bone cancer	0.00119	0.00124	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—bone cancer	0.00119	0.00124	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—bone cancer	0.00119	0.00124	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—bone cancer	0.00119	0.00124	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—bone cancer	0.00119	0.00124	CcSEcCtD
Naltrexone—Paraesthesia—Methotrexate—bone cancer	0.00118	0.00123	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00118	0.00123	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—bone cancer	0.00118	0.00123	CcSEcCtD
Naltrexone—Anorexia—Epirubicin—bone cancer	0.00118	0.00123	CcSEcCtD
Naltrexone—Dyspnoea—Methotrexate—bone cancer	0.00118	0.00123	CcSEcCtD
Naltrexone—Somnolence—Methotrexate—bone cancer	0.00117	0.00122	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—bone cancer	0.00116	0.00121	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—bone cancer	0.00115	0.0012	CcSEcCtD
Naltrexone—Decreased appetite—Methotrexate—bone cancer	0.00115	0.00119	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—bone cancer	0.00114	0.00119	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—bone cancer	0.00114	0.00119	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Methotrexate—bone cancer	0.00114	0.00119	CcSEcCtD
Naltrexone—Fatigue—Methotrexate—bone cancer	0.00114	0.00119	CcSEcCtD
Naltrexone—Infection—Doxorubicin—bone cancer	0.00113	0.00118	CcSEcCtD
Naltrexone—Pain—Methotrexate—bone cancer	0.00113	0.00118	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00112	0.00117	CcSEcCtD
Naltrexone—Shock—Doxorubicin—bone cancer	0.00112	0.00117	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—bone cancer	0.00112	0.00117	CcSEcCtD
Naltrexone—Insomnia—Epirubicin—bone cancer	0.00112	0.00116	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—bone cancer	0.00111	0.00116	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—bone cancer	0.00111	0.00116	CcSEcCtD
Naltrexone—Paraesthesia—Epirubicin—bone cancer	0.00111	0.00115	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—bone cancer	0.0011	0.00115	CcSEcCtD
Naltrexone—Dyspnoea—Epirubicin—bone cancer	0.0011	0.00115	CcSEcCtD
Naltrexone—Somnolence—Epirubicin—bone cancer	0.0011	0.00114	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—bone cancer	0.00109	0.00113	CcSEcCtD
Naltrexone—Feeling abnormal—Methotrexate—bone cancer	0.00109	0.00113	CcSEcCtD
Naltrexone—Gastrointestinal pain—Methotrexate—bone cancer	0.00108	0.00112	CcSEcCtD
Naltrexone—Decreased appetite—Epirubicin—bone cancer	0.00107	0.00112	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Epirubicin—bone cancer	0.00106	0.00111	CcSEcCtD
Naltrexone—Fatigue—Epirubicin—bone cancer	0.00106	0.00111	CcSEcCtD
Naltrexone—Pain—Epirubicin—bone cancer	0.00105	0.0011	CcSEcCtD
Naltrexone—Constipation—Epirubicin—bone cancer	0.00105	0.0011	CcSEcCtD
Naltrexone—Urticaria—Methotrexate—bone cancer	0.00105	0.00109	CcSEcCtD
Naltrexone—Body temperature increased—Methotrexate—bone cancer	0.00104	0.00109	CcSEcCtD
Naltrexone—Abdominal pain—Methotrexate—bone cancer	0.00104	0.00109	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00104	0.00108	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—bone cancer	0.00103	0.00108	CcSEcCtD
Naltrexone—Paraesthesia—Doxorubicin—bone cancer	0.00102	0.00107	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—bone cancer	0.00102	0.00106	CcSEcCtD
Naltrexone—Feeling abnormal—Epirubicin—bone cancer	0.00102	0.00106	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—bone cancer	0.00101	0.00106	CcSEcCtD
Naltrexone—Gastrointestinal pain—Epirubicin—bone cancer	0.00101	0.00105	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—bone cancer	0.000992	0.00103	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000985	0.00103	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—bone cancer	0.000984	0.00103	CcSEcCtD
Naltrexone—Urticaria—Epirubicin—bone cancer	0.00098	0.00102	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—bone cancer	0.000976	0.00102	CcSEcCtD
Naltrexone—Pain—Doxorubicin—bone cancer	0.000976	0.00102	CcSEcCtD
Naltrexone—Body temperature increased—Epirubicin—bone cancer	0.000975	0.00102	CcSEcCtD
Naltrexone—Abdominal pain—Epirubicin—bone cancer	0.000975	0.00102	CcSEcCtD
Naltrexone—Hypersensitivity—Methotrexate—bone cancer	0.000971	0.00101	CcSEcCtD
Naltrexone—Asthenia—Methotrexate—bone cancer	0.000946	0.000986	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—bone cancer	0.00094	0.000981	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—bone cancer	0.000933	0.000973	CcSEcCtD
Naltrexone—Pruritus—Methotrexate—bone cancer	0.000933	0.000972	CcSEcCtD
Naltrexone—Hypersensitivity—Epirubicin—bone cancer	0.000909	0.000948	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—bone cancer	0.000907	0.000945	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—bone cancer	0.000902	0.000941	CcSEcCtD
Naltrexone—Body temperature increased—Doxorubicin—bone cancer	0.000902	0.000941	CcSEcCtD
Naltrexone—Diarrhoea—Methotrexate—bone cancer	0.000902	0.00094	CcSEcCtD
Naltrexone—Asthenia—Epirubicin—bone cancer	0.000885	0.000923	CcSEcCtD
Naltrexone—Pruritus—Epirubicin—bone cancer	0.000873	0.00091	CcSEcCtD
Naltrexone—Dizziness—Methotrexate—bone cancer	0.000872	0.000909	CcSEcCtD
Naltrexone—Diarrhoea—Epirubicin—bone cancer	0.000844	0.00088	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—bone cancer	0.000841	0.000877	CcSEcCtD
Naltrexone—Vomiting—Methotrexate—bone cancer	0.000838	0.000874	CcSEcCtD
Naltrexone—Rash—Methotrexate—bone cancer	0.000831	0.000867	CcSEcCtD
Naltrexone—Dermatitis—Methotrexate—bone cancer	0.00083	0.000866	CcSEcCtD
Naltrexone—Headache—Methotrexate—bone cancer	0.000826	0.000861	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—bone cancer	0.000819	0.000854	CcSEcCtD
Naltrexone—Dizziness—Epirubicin—bone cancer	0.000816	0.000851	CcSEcCtD
Naltrexone—Pruritus—Doxorubicin—bone cancer	0.000807	0.000842	CcSEcCtD
Naltrexone—Vomiting—Epirubicin—bone cancer	0.000784	0.000818	CcSEcCtD
Naltrexone—Nausea—Methotrexate—bone cancer	0.000783	0.000816	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—bone cancer	0.000781	0.000814	CcSEcCtD
Naltrexone—Rash—Epirubicin—bone cancer	0.000778	0.000811	CcSEcCtD
Naltrexone—Dermatitis—Epirubicin—bone cancer	0.000777	0.00081	CcSEcCtD
Naltrexone—Headache—Epirubicin—bone cancer	0.000773	0.000806	CcSEcCtD
Naltrexone—Dizziness—Doxorubicin—bone cancer	0.000755	0.000787	CcSEcCtD
Naltrexone—Nausea—Epirubicin—bone cancer	0.000733	0.000764	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—bone cancer	0.000726	0.000757	CcSEcCtD
Naltrexone—Rash—Doxorubicin—bone cancer	0.00072	0.00075	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—bone cancer	0.000719	0.00075	CcSEcCtD
Naltrexone—Headache—Doxorubicin—bone cancer	0.000715	0.000746	CcSEcCtD
Naltrexone—Nausea—Doxorubicin—bone cancer	0.000678	0.000707	CcSEcCtD
Naltrexone—UGT1A1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000275	0.096	CbGpPWpGaD
Naltrexone—UGT1A1—Irinotecan Pathway—CYP3A4—bone cancer	0.000176	0.0613	CbGpPWpGaD
Naltrexone—UGT1A1—Estrogen metabolism—CYP3A4—bone cancer	0.000144	0.0502	CbGpPWpGaD
Naltrexone—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000126	0.044	CbGpPWpGaD
Naltrexone—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000118	0.0412	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000118	0.0412	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.000118	0.0411	CbGpPWpGaD
Naltrexone—UGT1A1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	9.07e-05	0.0317	CbGpPWpGaD
Naltrexone—OPRK1—Mecp2 and Associated Rett Syndrome—EZH2—bone cancer	8.33e-05	0.0291	CbGpPWpGaD
Naltrexone—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	6.9e-05	0.0241	CbGpPWpGaD
Naltrexone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	6.78e-05	0.0237	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—RGS1—bone cancer	4.79e-05	0.0167	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—GRM4—bone cancer	4.79e-05	0.0167	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—GRM4—bone cancer	4.2e-05	0.0147	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—RGS1—bone cancer	4.2e-05	0.0147	CbGpPWpGaD
Naltrexone—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	4.16e-05	0.0145	CbGpPWpGaD
Naltrexone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	3.96e-05	0.0138	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—GRM4—bone cancer	3.55e-05	0.0124	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—RGS1—bone cancer	3.55e-05	0.0124	CbGpPWpGaD
Naltrexone—UGT1A1—Phase II conjugation—GSTP1—bone cancer	3.45e-05	0.0121	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—GRM4—bone cancer	2.9e-05	0.0101	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	2.71e-05	0.00946	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—GRM4—bone cancer	2.54e-05	0.00888	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—GRM1—bone cancer	2.52e-05	0.00878	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—CYP3A4—bone cancer	2.36e-05	0.00824	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—CYP3A4—bone cancer	2.33e-05	0.00813	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—GSTP1—bone cancer	2.3e-05	0.00804	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—TGFBR2—bone cancer	2.3e-05	0.00804	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—GRM1—bone cancer	2.21e-05	0.0077	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—GRM4—bone cancer	2.15e-05	0.00751	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	2.13e-05	0.00744	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—GSTP1—bone cancer	2.02e-05	0.00705	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—GSTP1—bone cancer	1.99e-05	0.00695	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—GRM1—bone cancer	1.86e-05	0.00651	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—SMO—bone cancer	1.77e-05	0.00619	CbGpPWpGaD
Naltrexone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	1.73e-05	0.00603	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—GRM4—bone cancer	1.64e-05	0.00573	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—RGS1—bone cancer	1.64e-05	0.00573	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—SMO—bone cancer	1.55e-05	0.00543	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—JUN—bone cancer	1.55e-05	0.00541	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—GRM4—bone cancer	1.49e-05	0.0052	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—RGS1—bone cancer	1.49e-05	0.0052	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—GRM4—bone cancer	1.44e-05	0.00502	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—RGS1—bone cancer	1.44e-05	0.00502	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—GRM1—bone cancer	1.42e-05	0.00496	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NDUFA12—bone cancer	1.42e-05	0.00494	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	1.41e-05	0.00493	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—SMO—bone cancer	1.31e-05	0.00459	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—RGS1—bone cancer	1.31e-05	0.00456	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—GRM4—bone cancer	1.31e-05	0.00456	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—GRM1—bone cancer	1.29e-05	0.00451	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—GRM1—bone cancer	1.25e-05	0.00435	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—GRM4—bone cancer	1.22e-05	0.00424	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—RGS1—bone cancer	1.22e-05	0.00424	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	1.2e-05	0.00419	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NT5C3A—bone cancer	1.17e-05	0.0041	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—GRM1—bone cancer	1.13e-05	0.00395	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—GRM4—bone cancer	1.1e-05	0.00385	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—RGS1—bone cancer	1.1e-05	0.00385	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	1.09e-05	0.00382	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—GRM1—bone cancer	1.05e-05	0.00368	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	9.96e-06	0.00348	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	9.83e-06	0.00343	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—GRM1—bone cancer	9.57e-06	0.00334	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	9.31e-06	0.00325	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—GNA11—bone cancer	9.16e-06	0.0032	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—SMO—bone cancer	9.1e-06	0.00318	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GRM4—bone cancer	8.8e-06	0.00307	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RGS1—bone cancer	8.8e-06	0.00307	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	8.33e-06	0.00291	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—GNA11—bone cancer	8.32e-06	0.0029	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—IL3—bone cancer	8.31e-06	0.0029	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.31e-06	0.0029	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—GNA11—bone cancer	8.04e-06	0.0028	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—SMO—bone cancer	7.98e-06	0.00278	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RGS1—bone cancer	7.71e-06	0.00269	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GRM4—bone cancer	7.71e-06	0.00269	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GRM1—bone cancer	7.63e-06	0.00266	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL3—bone cancer	7.54e-06	0.00263	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—GNA11—bone cancer	7.3e-06	0.00255	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL3—bone cancer	7.28e-06	0.00254	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.17e-06	0.0025	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—GNA11—bone cancer	6.79e-06	0.00237	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—SMO—bone cancer	6.74e-06	0.00235	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GRM1—bone cancer	6.69e-06	0.00234	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL3—bone cancer	6.62e-06	0.00231	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GRM4—bone cancer	6.52e-06	0.00228	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RGS1—bone cancer	6.52e-06	0.00228	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NDUFA12—bone cancer	6.49e-06	0.00227	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.18e-06	0.00216	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—GNA11—bone cancer	6.17e-06	0.00215	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL3—bone cancer	6.16e-06	0.00215	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GRM1—bone cancer	5.65e-06	0.00197	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL3—bone cancer	5.59e-06	0.00195	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NT5C3A—bone cancer	5.38e-06	0.00188	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SMO—bone cancer	5.37e-06	0.00188	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ENO2—bone cancer	5.14e-06	0.00179	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GNA11—bone cancer	4.92e-06	0.00172	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—DHFR—bone cancer	4.77e-06	0.00166	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SMO—bone cancer	4.71e-06	0.00165	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.58e-06	0.0016	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ATF1—bone cancer	4.57e-06	0.0016	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL3—bone cancer	4.46e-06	0.00156	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GNA11—bone cancer	4.46e-06	0.00156	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.41e-06	0.00154	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GNA11—bone cancer	4.31e-06	0.0015	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP3A4—bone cancer	4.04e-06	0.00141	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ATF1—bone cancer	4.01e-06	0.0014	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SMO—bone cancer	3.98e-06	0.00139	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.98e-06	0.00139	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL3—bone cancer	3.91e-06	0.00136	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFBR2—bone cancer	3.81e-06	0.00133	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GNA11—bone cancer	3.64e-06	0.00127	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1R—bone cancer	3.59e-06	0.00125	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTP1—bone cancer	3.45e-06	0.00121	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ATF1—bone cancer	3.39e-06	0.00118	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFBR2—bone cancer	3.34e-06	0.00117	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL3—bone cancer	3.3e-06	0.00115	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1R—bone cancer	3.14e-06	0.0011	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.13e-06	0.00109	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFBR2—bone cancer	2.82e-06	0.000986	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1R—bone cancer	2.66e-06	0.000928	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.63e-06	0.000917	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KIT—bone cancer	2.6e-06	0.000908	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BRAF—bone cancer	2.44e-06	0.000853	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—bone cancer	2.37e-06	0.000827	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ENO2—bone cancer	2.36e-06	0.000823	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KIT—bone cancer	2.28e-06	0.000796	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—DHFR—bone cancer	2.19e-06	0.000763	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BRAF—bone cancer	2.14e-06	0.000748	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—bone cancer	2.08e-06	0.000725	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MDM2—bone cancer	2.05e-06	0.000715	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GNA11—bone cancer	2.04e-06	0.000713	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KIT—bone cancer	1.93e-06	0.000673	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP3A4—bone cancer	1.85e-06	0.000647	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BRAF—bone cancer	1.81e-06	0.000632	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MDM2—bone cancer	1.8e-06	0.000627	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—bone cancer	1.79e-06	0.000625	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JUN—bone cancer	1.78e-06	0.000622	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—bone cancer	1.76e-06	0.000613	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—bone cancer	1.73e-06	0.000605	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTP1—bone cancer	1.58e-06	0.000553	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JUN—bone cancer	1.56e-06	0.000545	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—bone cancer	1.52e-06	0.00053	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MDM2—bone cancer	1.52e-06	0.00053	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—bone cancer	1.4e-06	0.000489	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JUN—bone cancer	1.32e-06	0.000461	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—bone cancer	1.28e-06	0.000448	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—bone cancer	1.23e-06	0.000428	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—bone cancer	1.18e-06	0.00041	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—bone cancer	1.04e-06	0.000362	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—bone cancer	1.03e-06	0.00036	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—bone cancer	8.71e-07	0.000304	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—bone cancer	8.21e-07	0.000287	CbGpPWpGaD
